Precise dosing of a strong antibiotic for ICU patients with resistant infections
Treatments studied
Part of Infections clinical trials.
This study tests a precise dosing approach for the antibiotic ceftazidime-avibactam to treat serious infections in ICU patients. It aims to help people with hard-to-treat bacteria that are resistant to many other antibiotics.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 85 years old.
- You are currently in the ICU with a severe infection (like sepsis).
- You have a type of bacteria that is resistant to a common antibiotic called carbapenem.
- You have not used the study drug (ceftazidime-avibactam) in the last 15 days.
- You are able to provide samples (like sputum, blood, or fluid) for testing before starting the drug.
- You are willing to receive the drug through an IV for at least 72 hours and follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an antibiotic called ceftazidime-avibactam for people with serious infections like bloodstream infections or pneumonia that started in the hospital or from a breathing machine. It aims to start treatment quickly after identifying the bacteria.
This trial tests whether giving the antibiotic ceftazidime-avibactam continuously or intermittently works better for ICU patients with severe infections caused by drug-resistant bacteria. The goal is to see which method improves outcomes.
This trial tests two ways of giving the antibiotic ceftazidime/avibactam (a powerful drug for resistant bacteria) to critically ill patients in the ICU. The goal is to see if a continuous infusion works better than standard timed doses.
This trial tests if adjusting ceftazidime (a powerful antibiotic) early on helps treat serious infections better in intensive care patients. You may qualify if you are in the ICU and your doctor is considering starting this antibiotic.
This trial tests two different schedules of a combination of antibiotics (ceftazidime-avibactam plus aztreonam) for people with serious infections caused by bacteria that are hard to treat. It aims to find the best way to give these medicines.
This study tests whether combining two antibiotics (ceftazidime and fosfomycin) works better than ceftazidime alone for hospitalized adults with serious bacterial infections. If you have a severe infection thought to be caused by Gram-negative bacteria, this trial may offer a new treatment option.
Hear when a new ECMO trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.